Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies

Here we describe, to our knowledge, the first case where an evolution of mechanisms responsible for hypercalcemia occurred in undifferentiated thymic carcinoma and discuss specific management strategies for hypercalcemia of malignancy (HCM). Case Description. We report a 26-year-old male with newly...

Full description

Saved in:
Bibliographic Details
Main Authors: Cheng Cheng, Jose Kuzhively, Sanford Baim
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Case Reports in Endocrinology
Online Access:http://dx.doi.org/10.1155/2017/2608392
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832552815303589888
author Cheng Cheng
Jose Kuzhively
Sanford Baim
author_facet Cheng Cheng
Jose Kuzhively
Sanford Baim
author_sort Cheng Cheng
collection DOAJ
description Here we describe, to our knowledge, the first case where an evolution of mechanisms responsible for hypercalcemia occurred in undifferentiated thymic carcinoma and discuss specific management strategies for hypercalcemia of malignancy (HCM). Case Description. We report a 26-year-old male with newly diagnosed undifferentiated thymic carcinoma associated with HCM. Osteolytic metastasis-related hypercalcemia was presumed to be the etiology of hypercalcemia that responded to intravenous hydration and bisphosphonate therapy. Subsequently, refractory hypercalcemia persisted despite the administration of bisphosphonates and denosumab indicative of refractory hypercalcemia. Elevated 1,25-dihydroxyvitamin D was noted from the second admission with hypercalcemia responding to glucocorticoid administration. A subsequent PTHrP was also elevated, further supporting multiple mechanistic evolution of HCM. The different mechanisms of HCM are summarized with the role of tailoring therapies based on the particular mechanism underlying hypercalcemia discussed. Conclusion. Our case illustrates the importance of a comprehensive initial evaluation and reevaluation of all identifiable mechanisms of HCM, especially in the setting of recurrent and refractory hypercalcemia. Knowledge of the known and possible evolution of the underlying mechanisms for HCM is important for application of specific therapies that target those mechanisms. Specific targeting therapies to the underlying mechanisms for HCM could positively affect patient outcomes.
format Article
id doaj-art-ddd11b8d21cf4a6b8590b74a64f3ca44
institution Kabale University
issn 2090-6501
2090-651X
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Case Reports in Endocrinology
spelling doaj-art-ddd11b8d21cf4a6b8590b74a64f3ca442025-02-03T05:57:48ZengWileyCase Reports in Endocrinology2090-65012090-651X2017-01-01201710.1155/2017/26083922608392Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted TherapiesCheng Cheng0Jose Kuzhively1Sanford Baim2Division of Endocrinology and Metabolism, Rush University Medical Center, Chicago, IL, USADivision of Endocrinology and Metabolism, Rush University Medical Center, Chicago, IL, USADivision of Endocrinology and Metabolism, Rush University Medical Center, Chicago, IL, USAHere we describe, to our knowledge, the first case where an evolution of mechanisms responsible for hypercalcemia occurred in undifferentiated thymic carcinoma and discuss specific management strategies for hypercalcemia of malignancy (HCM). Case Description. We report a 26-year-old male with newly diagnosed undifferentiated thymic carcinoma associated with HCM. Osteolytic metastasis-related hypercalcemia was presumed to be the etiology of hypercalcemia that responded to intravenous hydration and bisphosphonate therapy. Subsequently, refractory hypercalcemia persisted despite the administration of bisphosphonates and denosumab indicative of refractory hypercalcemia. Elevated 1,25-dihydroxyvitamin D was noted from the second admission with hypercalcemia responding to glucocorticoid administration. A subsequent PTHrP was also elevated, further supporting multiple mechanistic evolution of HCM. The different mechanisms of HCM are summarized with the role of tailoring therapies based on the particular mechanism underlying hypercalcemia discussed. Conclusion. Our case illustrates the importance of a comprehensive initial evaluation and reevaluation of all identifiable mechanisms of HCM, especially in the setting of recurrent and refractory hypercalcemia. Knowledge of the known and possible evolution of the underlying mechanisms for HCM is important for application of specific therapies that target those mechanisms. Specific targeting therapies to the underlying mechanisms for HCM could positively affect patient outcomes.http://dx.doi.org/10.1155/2017/2608392
spellingShingle Cheng Cheng
Jose Kuzhively
Sanford Baim
Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies
Case Reports in Endocrinology
title Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies
title_full Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies
title_fullStr Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies
title_full_unstemmed Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies
title_short Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies
title_sort hypercalcemia of malignancy in thymic carcinoma evolving mechanisms of hypercalcemia and targeted therapies
url http://dx.doi.org/10.1155/2017/2608392
work_keys_str_mv AT chengcheng hypercalcemiaofmalignancyinthymiccarcinomaevolvingmechanismsofhypercalcemiaandtargetedtherapies
AT josekuzhively hypercalcemiaofmalignancyinthymiccarcinomaevolvingmechanismsofhypercalcemiaandtargetedtherapies
AT sanfordbaim hypercalcemiaofmalignancyinthymiccarcinomaevolvingmechanismsofhypercalcemiaandtargetedtherapies